We found that failing human hearts with DCM and elevated gelsolin actin-depolymerizing activity responded to LVAD therapy by a marked improvement in cytoskeletal integrity possibly due to reduced Ca2+ influx reducing Ca2+-dependent activation of gelsolin and its severing activity thus improving cytoskeletal integrity (Fig. 8d). The gene discussed is GSN; the disease is familial dilated cardiomyopathy.